Analysts expect MannKind to report Q2 2026 revenue of $108.8 million and a loss of $0.02 per share, while the stock currently trades around $3.95 compared to a consensus price target of $9.34.
Investors are primarily focused on the commercial execution of the recently approved Furoscix ReadyFlow Autoinjector and the pediatric expansion of Afrezza, alongside the continued growth of Tyvaso DPI royalties.
Management recently highlighted 2026 as the most catalyst-rich year in the company's history following the late-July FDA approval of the ReadyFlow device.
The market is looking for confirmation that these regulatory milestones are translating into hospital adoption and payer coverage to support the company's ambitious 2026 revenue run rate goals.